The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. The subject invention also provides for pharmaceutical oral unit dosage forms of 0.6 mg laquinimod for use in reducing the relapse rate and/or for use in reducing the accumulation of physical disability in a relapsing- remitting multiple sclerosis human patient.
申请公布号
WO2010147665(A1)
申请公布日期
2010.12.23
申请号
WO2010US01759
申请日期
2010.06.18
申请人
TEVA PHARMACEUTICAL INDUSTRIES LTD.;TEVA PHARMACEUTICALS USA INC.;TARCIC, NORA;BAR-ZOHAR, DAN;KOFLER, DINA